XML 37 R26.htm IDEA: XBRL DOCUMENT

Restructuring, Impairment and Related Charges (Tables)

3 Months Ended

Jun. 30, 2020

Restructuring and Related Activities [Abstract]

Restructuring, Impairment and Related Costs

Restructuring, impairment and related charges during the three months ended June 30, 2020 consisted of the following:


	Three Months Ended June 30, 2020
(In millions)	U.S. Pharmaceutical and Specialty Solutions		European Pharmaceutical Solutions ⁽¹⁾		Medical-Surgical Solutions		Other		Corporate ⁽¹⁾		Total
Severance and employee-related costs, net	$	1	$	13	$	—	$	4	$	20	$	38
Exit and other-related costs ⁽²⁾	1		1		3		1		7		13
Asset impairments and accelerated depreciation	—		4		—		—		1		5
Total	$	2	$	18	$	3	$	5	$	28	$	56

(1)Primarily represents costs associated with the operating model and cost optimization efforts described above.

(2)Exit and other-related costs primarily consist of project consulting fees.

Fiscal 2020

Restructuring, impairment and related charges during the three months ended June 30, 2019 consisted of the following:


	Three Months Ended June 30, 2019
(In millions)	U.S. Pharmaceutical and Specialty Solutions ⁽¹⁾		European Pharmaceutical Solutions⁽¹⁾		Medical-Surgical Solutions ⁽²⁾		Other⁽²⁾		Corporate⁽³⁾		Total
Severance and employee-related costs, net	$	(1)	$	(1)	$	—	$	—	$	6	$	4
Exit and other-related costs ⁽⁴⁾	—		1		2		1		10		14
Asset impairments and accelerated depreciation	—		3		1		—		1		5
Total	$	(1)	$	3	$	3	$	1	$	17	$	23

(1)Represents costs associated with the operating model and cost optimization efforts described above.

(2)Represents costs associated with a growth initiative which included a reduction in workforce, facility consolidation, and store closures. These initiatives were substantially completed in the year ended March 31, 2020.

(3)Represents costs associated with the operating model cost optimization efforts and with the relocation of the Company’s corporate headquarters described above.

(4)Exit and other-related costs primarily include project consulting fees.

Schedule of Restructuring and Asset Impairment Charges

The following table summarizes the activity related to the restructuring liabilities associated with the Company’s restructuring initiatives for the three months ended June 30, 2020:


(In millions)	U.S. Pharmaceutical and Specialty Solutions		European Pharmaceutical Solutions		Medical-Surgical Solutions		Other		Corporate		Total
Balance, March 31, 2020 ⁽¹⁾	$	24	$	56	$	20	$	18	$	39	$	157
Restructuring, impairment and related charges	2		18		3		5		28		56
Non-cash charges	—		(4)		—		—		(1)		(5)
Cash payments	(7)		(3)		—		(5)		(16)		(31)
Other	—		(2)		(4)		—		(3)		(9)
Balance, June 30, 2020 ⁽²⁾	$	19	$	65	$	19	$	18	$	47	$	168

(1)As of March 31, 2020, the total reserve balance was $157 million, of which $118 million was recorded in Other accrued liabilities and $39 million was recorded in Other non-current liabilities.

(2)As of June 30, 2020, the total reserve balance was $168 million, of which $141 million was recorded in Other accrued liabilities and $27 million was recorded in Other non-current liabilities.